Section One: Overview and Determination

Please find below a statement of our determination as to whether or not the committee views the Masgutova Method or Masgutova Neurosensorimotor Reflex Integration (MNRI) as a proven and effective treatment for children with autism spectrum disorder and/or other developmental disabilities. In subsequent sections you will find documentation of our review process including a description of the proposed treatment, a synopsis of review findings, the treatment review evidence checklist, and a listing of the literature considered. In reviewing treatments presented to us by DHS/DLTC, we implement a review process that carefully and fully considers all available information regarding a proposed treatment. Our determination is limited to a statement regarding how established a practice is in regard to quality research. We do not make funding decisions.

Description of proposed treatment
The website associated with the MNRI Method states the Masgutova Neurosensorimotor Reflex Integration (MNRI) Method is comprised of a number of integration programs, each designed to reinforce and optimize the integration of primary motor reflex patterns. As found in the initial review, no single, clearly defined intervention or treatment package was found within the extant materials promoting the practice. The following link is to the website promoting/selling the practice: http://masgutovamethod.com/about-the-method/how-mnri-method-works

Synopsis of review
In the case of the Masgutova Method or Masgutova Neurosensorimotor Reflex Integration, please refer to the attached reference listing that details the reviewed research. The committee’s conclusions regarding this therapy include:

The materials found related to the Masgutova Method did not include any experimental studies. While the founder of the practice claims to have helped thousands of individuals with the therapy, no data or research were provided, only “inspirational stories.” A review of Ebscohost and other academic search engines found no research or other articles pertaining to the Masgutova Method. For the first review an internet search found two resources (both by the creator of the treatment) and a website promoting the practice. The website identified research that supports the theory behind the approach as well as a number of testimonials, but no applied research. For this review, one research article was found. This research
had several major design flaws. Furthermore, it did not measure clinical or behavioral outcomes. Instead, it included a measure of brain wave activity.

In sum, it is the decision of the committee that the Masgutova Method or Masgutova Neurosensorymotor Reflex Integration remains a level 5, untested treatment, as there are no experimental studies that have tested its effectiveness. There is no evidence to suggest that it is harmful.
Section Two: Rationale for Focus on Research Specific to Comprehensive Treatment Packages (CTP) or Models

In the professional literature, there are two classifications of interventions for individuals with Autism Spectrum Disorder (National Research Council, 2001; Odom et al., 2003; Rogers & Vismara, 2008):

(a) Focused intervention techniques are individual practices or strategies (such as positive reinforcement) designed to produce a specific behavioral or developmental outcome, and

(b) Comprehensive treatment models are “packages” or programs that consist of a set of practices or multiple techniques designed to achieve a broader learning or developmental impact.

To determine whether a treatment package is proven and effective, the Treatment Intervention Advisory Committee (TIAC) will adopt the following perspective as recommended by Odom et al. (2010):

The individual, focused intervention techniques that make up a comprehensive treatment model may be evidence-based. The research supporting the effectiveness of separate, individual components, however, does not constitute an evaluation of the comprehensive treatment model or “package.” The TIAC will consider and review only research that has evaluated the efficacy of implementing the comprehensive treatment as a package. Such packages are most often identifiable in the literature by a consistently used name or label.


Section Three: DLTC-TIAC Treatment Review Evidence Checklist

Name of Treatment: Masgutova Method/MNRI

**Level 1 – Well Established or Strong Evidence (DHS 107 - Proven & Effective Treatment)**

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, National Professional Development Center) have approved of or rated the treatment package as having a strong evidence base; authorities are in agreement about the level of evidence.
- There exist ample high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
- Minimum of two group studies or five single subject studies or a combination of the two.
- Studies were conducted across at least two independent research groups.
- Studies were published in peer reviewed journals.
- Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research

**Level 2 – Established or Moderate Evidence (DHS 107 - Proven & Effective Treatment)**

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have approved of or rated the treatment package as having at least a minimal evidence base; authorities may not be in agreement about the level of evidence.
- There exist at least two high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
- Minimum of one group study or two single subject studies or a combination of the two.
- Studies were conducted by someone other than the creator/provider of the treatment.
- Studies were published in peer reviewed journals.
- Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research
Level 3 – Emerging Evidence (DHS 107 – Promising as a Proven & Effective Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have recognized the treatment package as having an emerging evidence base; authorities may not be in agreement about the level of evidence.

☐ There exists at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.

☐ May be one group study or single subject study.

☐ Study was conducted by someone other than the creator/provider of the treatment.

☐ Study was published in peer reviewed journal.

☐ Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research

Level 4 – Insufficient Evidence (Experimental Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☐ There is not at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.

☐ Study was conducted by the creator/provider of the treatment.

☐ Study was not published in a peer reviewed journal.

☐ Participants (i.e., N) are not clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes:
Level 5 – Untested (Experimental Treatment) &/or Potentially Harmful

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.
- There are no published studies supporting the proposed treatment package.

- There exists evidence that the treatment package is potentially harmful.
  - Authoritative bodies have expressed concern regarding safety/outcomes.
  - Professional bodies (i.e., organizations or certifying bodies) have created statements regarding safety/outcomes.

Notes: At this level, please specify if the treatment is reported to be potentially harmful, providing documentation

Date: April 24, 2015

Committee Members Completing Initial Review of Research Base: Lana Collet-Klingenberg, Jeffrey Tiger

Committee Decision on Level of Evidence to Suggest the Proposed Treatment is Proven and Effective: Level 5 – Untested/Experimental Treatment (no evidence that it is harmful)

References Supporting Identification of Evidence Levels:
Section Four: Literature Review


http://masgutovamethod.com (© 2014 Svetlana Masgutova Educational Institute. All Rights Reserved)